Our Q3 2023 earnings report

October 26, 2023

Share this article


article hero thumbnail

Merck’s (NYSE: MRK) Q3 2023 results reflect sustained growth, particularly in oncology and vaccines. Our company announced Q3 worldwide sales of $16.0 billion, an increase of 7% from Q3 2022. ​

“Our strong results this quarter reflect our talented team’s commitment to bringing forward important innovation and pursuing breakthroughs for all those who count on us,” said Rob Davis, chairman and chief executive officer, Merck. “We continue to push the boundaries of science, making disciplined investments to augment our diverse pipeline and applying our expertise to accelerate potentially transformative treatments to address patient needs — including through our recently announced collaboration with Daiichi Sankyo. I am proud of our progress as we continue to execute at the highest level and work to generate strong and sustainable value, today and well into the future.” ​

Merck anticipates full-year 2023 worldwide sales to be between $59.7 billion and $60.2 billion.​

Take a look at the infographic below for more details on Q3 2023 results

Download infographic